| Dr Neil Manu Gupta, MD | |
|
4201 W Medical Center Dr, Mchenry, IL 60050-8409 | |
| (815) 334-5566 | |
| (815) 759-4008 |
| Full Name | Dr Neil Manu Gupta |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 20 Years |
| Location | 4201 W Medical Center Dr, Mchenry, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205033248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 036124219 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Honorhealth Scottsdale Shea Medical Center | Scottsdale, AZ | Hospital |
| Scottsdale Osborn Medical Center | Scottsdale, AZ | Hospital |
| The University Of Chicago Medical Center | Chicago, IL | Hospital |
| John C. Lincoln North Mountain Hospital | Phoenix, AZ | Hospital |
| Honorhealth Deer Valley Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sonoran Radiology Ltd | 3375964505 | 367 |
| Southwest Diagnostic Imaging Ltd | 7416946199 | 87 |
| University Of Chicago | 7719899426 | 1137 |
| Southwest Diagnostic Imaging Ltd | 7416946199 | 87 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | The University Of Chicago Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Illinois Bone And Joint Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205922432 PECOS PAC ID: 6002814878 Enrollment ID: O20061110000331 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20080814000765 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Pronet Imaging Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528099488 PECOS PAC ID: 5890722755 Enrollment ID: O20130221000128 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Specialists In Medical Imaging Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841687951 PECOS PAC ID: 2163733544 Enrollment ID: O20150626000251 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Beverly Radiology Medical Group Iii |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962457812 PECOS PAC ID: 3476466376 Enrollment ID: O20150908000430 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Southwest Diagnostic Imaging Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902896236 PECOS PAC ID: 7416946199 Enrollment ID: O20190115001857 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Personal Health Imaging Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083659379 PECOS PAC ID: 1658262407 Enrollment ID: O20190521001541 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Medford Radiological Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407938111 PECOS PAC ID: 2062303324 Enrollment ID: O20200408001204 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Sonoran Radiology Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033745708 PECOS PAC ID: 3375964505 Enrollment ID: O20201112000418 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | Millennium Medical Imaging Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235114182 PECOS PAC ID: 5799776910 Enrollment ID: O20210908003088 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477262046 PECOS PAC ID: 7719899426 Enrollment ID: O20230206002554 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Neil Manu Gupta, MD 4201 W Medical Center Dr, Mchenry, IL 60050-8409 Ph: (815) 334-5566 | Dr Neil Manu Gupta, MD 4201 W Medical Center Dr, Mchenry, IL 60050-8409 Ph: (815) 334-5566 |
News Archive
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease.
Receiving a blood transfusion in the intensive care unit (ICU) is not uncommon, but reliable predictors for patients that will require transfusion are not readily available. A new study published in the May issue of Anesthesiology seeks to reduce the occurrence of ICU transfusions, revealing a new marker for patients at higher risk for developing severe anemia and subsequently requiring transfusion in the ICU.
A non-surgical procedure, called percutaneous coronary intervention, along with prescribed medication, is better than medication alone as initial treatment for people who have the most common form of heart disease, suggests an analysis of an international clinical trial co-led by St. Michael's Hospital.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.
› Verified 1 days ago
Ernest A Conti, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr Ste B203, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Abhijit Patil, Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Matthew Groenwald, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
James T Link, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3929 Mercy Dr, Mchenry, IL 60050 Phone: 815-759-0800 Fax: 815-759-2367 | |
Milton W Hummel, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3929 Mercy Dr, Mchenry, IL 60050 Phone: 815-759-0800 Fax: 815-759-2367 | |
Dr. Aaron Wittenberg, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 | |
Balatripura Voruganti, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4201 W Medical Center Dr, Mchenry, IL 60050 Phone: 815-334-5566 Fax: 815-759-4008 |